Inclusion Criteria Patients with chronic kidney disease aged between 18 and 80 years. Patients who are scheduled to initiate renal replacement therapy, either hemodialysis or peritoneal dialysis, within 3 months prior to the initiation of activated charcoal treatment. Patients with residual urine output greater than 200 mL per day. Exclusion Criteria Patients with a history of gastrointestinal diseases, including gastrointestinal bleeding, gastrointestinal obstruction, gastrointestinal mali
Conditions
Interventions
Activated charcoal materials share a common fundamental adsorption mechanism, namely physical adsorption physisorption. Activated charcoal is a spherical activated carbon formulation developed as an o
Experimental Dietary Supplement
Sponsors
Siriraj Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1) Patients with chronic kidney disease aged between 18 and 80 years. 2) Patients who are scheduled to initiate renal replacement therapy, either hemodialysis or peritoneal dialysis, within 3 months prior to the initiation of activated charcoal treatment. 3) Patients with residual urine output greater than 200 mL per day.
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1) Patients with a history of gastrointestinal diseases, including gastrointestinal bleeding, gastrointestinal obstruction, gastrointestinal malignancies, or severe gastrointestinal infections. 2) Patients with a history of gastric or intestinal surgery. 3) Patients with a history of severe liver diseases, such as liver cirrhosis, hepatitis, or hepatocellular carcinoma. Patients with serum albumin levels less than 2.0 g/dL. 4) Patients who are pregnant or breastfeeding. 5) Patients who have undergone kidney transplantation. 6) Patients diagnosed with active infections or any type of malignancy for which treatment has not yet been completed. 7) Patients receiving medications with a narrow therapeutic index, such as amiodarone, phenytoin, or digoxin. Patients with incomplete or inadequate data in the database that are unsuitable for statistical analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uremic toxins (IS/pCS) Outcomes are assessed at baseline (Visit 2) and at Weeks 12, 16 to 18, and 24 after initiation of activated charcoal (5 g/day) Protein bound uremic toxins indoxyl sulfate p-cresyl sulfate phenyl sulfate and imidazole propionate are measured in blood urine and feces using LCMSMS | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR eGFR are assessed at baseline (Visit 2) and at Weeks 12, 16 to 18, and 24 after initiation of activated charcoal (5 g/day) Renal function is assessed by eGFR (mL/min/1.73 m2), residual urine volume by 24-hour urine collection (mL/day), and uremic symptoms by questionnaires. | — |
Countries
Thailand
Contacts
Public ContactSukit Ruksasuk
Siriraj Hospital
Outcome results
None listed